Eli Lilly and Company (NYSE: LLY) announced that its diabetes drug candidate Foundayo (orforglipron) met the primary endpoint in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE